Granted Patent
B2
US 12,496,338 · App. 16/758,516 · Granted Dec 16, 2025
CAR for treatment of HIV infection
Inventors:
John Zaia (Duarte, CA); Kevin Morris (Duarte, CA); Xiuli Wang (Temple City, CA); Stephen J. Forman (Duarte, CA)
Assignee:
City of Hope
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treatment for HIV employing T cells expressing both a chimeric antigen receptors targeted to HIV and a CMV-specific T cell receptor.
Claims (7)
1 . A nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO:39 or the amino acid sequence of amino acids 1-649 of SEQ ID NO: 39.
2 . A vector comprising the nucleic acid molecule of claim 1 .
3 . A population of T cells comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising the amino acid sequence selected from: SEQ ID NO:39 and the amino acids 1-649 of SEQ ID NO:39.
4 . The population of T cells of claim 3 , wherein the T cells express a T cell receptor that binds a cytomegalovirus antigen.
5 . A chimeric antigen receptor (CAR) comprising the amino acid sequence selected from: SEQ ID NO:39 and the amino acids 1-649 of SEQ ID NO:39.
6 . A population of T cells comprising a chimeric antigen receptor (CAR) comprising the amino acid sequence selected from: SEQ ID NO:39 and the amino acids 1-649 of SEQ ID NO: 39.
7 . The population of T cells of claim 6 , wherein the T cells express a T cell receptor specific for a cytomegalovirus antigen.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 19, 2024
From: FORMAN, STEPHEN J.
To: CITY OF HOPE
Reel/Frame 068330/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 24, 2022
From: ZAIA, JOHN; MORRIS, KEVIN; WANG, XIULI
To: CITY OF HOPE
Reel/Frame 058738/0238 →
Continuity (2)
Provisional Application
62576063
· Oct 23, 2017
References Cited (70)
US 8580276B2
· Diamond et al.
· 2013
[cited by applicant]
WO WO2007140222
· 2007
[cited by applicant]
WO WO2016154628
· 2016
[cited by applicant]
WO WO2016154003A1
· 2016
[cited by examiner]
WO WO2017053556
· 2017
[cited by applicant]
Ali A, Kitchen SG, Chen ISY, Ng HL, Zack JA, Yang OO. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. J Virol. Jul. 11, 2016;90(15):6999-7006. (Year: 2016).
[cited by examiner]
Huang et al 2016. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. Nov. 15, 2016;45(5):1108-1121. (Year: 2016).
[cited by examiner]
Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of …
[cited by examiner]
Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive …
[cited by examiner]
Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell recep…
[cited by examiner]
Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang WC, Thomas SH, Brown CE, La Rosa C, Diamond DJ, Jensen MC, Nakamura R, Zaia JA, Forman SJ. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred C…
[cited by examiner]
Hale et al., “Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells,” Mol. Ther., Mar. 1, 2017, 25(3):570-579.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/057124, mailed on Apr. 16, 2019, 21 pages.
[cited by applicant]
Wang et al., “CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells,” Clin Cancer Res., Apr. 2, 2015, 21(13):2993-3002.
[cited by applicant]
Wu et al., “106: Stimulation, transduction, and expansion of CMV-specific T cells for adoptive immunotherapy in NHP,” Journal of Medical Primatology, Jul. 31, 2017, 46(4), Sp. Iss. SI, p. 207.
[cited by applicant]
Ali et al., “HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies,” J Virology., 2016, 90:6999-7006.
[cited by applicant]
Bailus et al., “Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain,” Mol Ther., 2016, 24(3):548-555.
[cited by applicant]
Bitton et al., “Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells,” Front Biosci., 1999, 4:D386-D393.
[cited by applicant]
Day et al., “PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and disease progression,” Nature, Sep. 21, 2006, 443(7109):350-354.
[cited by applicant]
Deeks et al., “A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy,” Mol Ther., 2002, 5(6):788-797.
[cited by applicant]
Gattinoni et al., “Paths to sternness: building the ultimate antitumour T cell,” Nat Rev Cancer, Oct. 2012, 12(10):671-684.
[cited by applicant]
Ghoneim et al., “Cell Intrinsic Barriers of T Cell-Based Immunotherapy,” Trends Mol Med., Dec. 2016, 22(12):1000-1011.
[cited by applicant]
Golubovskaya et al., “Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy,” Cancers, Mar. 15, 2016, 8(3):36.
[cited by applicant]
Gomez-Mora et al., “Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery,” Sep. 21, 2017, 12(9):e0184433.
[cited by applicant]
Hale et al., “Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells,” Mol Ther Methods Clin Dev., Jan. 10, 2017, 4:192-203.
[cited by applicant]
Hege et al., “Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice,” J Exp Med., Dec. 1, 1996, 184(6):2261-2269.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2020/025335, dated Jun. 16, 2020, 15 pages.
[cited by applicant]
Larbi et al., “truly naive” to “exhausted senescent” T cells: when markers predict functionality, Cytometry A., Jan. 2014, 85(1):25-35.
[cited by applicant]
Liu et al., “Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV,” Protein Cell, 2017, 8(12):861-877.
[cited by applicant]
Malinkova et al., “Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014),” Expert Opin Ther Pat., Jul. 10, 2015, 25(9):953-970.
[cited by applicant]
Peters and Sette et al., “NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence,” PLOS One, Aug. 29, 2007, 2(8):e796.
[cited by applicant]
Saayman et al., “Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex,” Mol Ther., 2016, 24(3):488-498.
[cited by applicant]
Sahu et al., “Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells,” Virology, 2013, 446(1-2):268-275.
[cited by applicant]
Shingai et al., “Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia,” Nature, 2013, 503:277-280.
[cited by applicant]
Sylwester et al., “Broadly targeted human cytomegalovirus-specific CD4 + and CD8 + T cells dominate the memory compartments of exposed subjects,” J Exp Med., 2005, 202(5):673-685.
[cited by applicant]
Trautmann et al., Upregulation of PD-1 expression on HIV-specific CDS+ T cells leads to reversible immune dysfunction, Nat Med., Oct. 2006, 12(10):1198-1202.
[cited by applicant]
Wang et al., “A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells,” Blood, 2011, 118(5):1255-1263.
[cited by applicant]
Wang et al., “Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines,” Vaccine, 2010, 28(6):1547-1557.
[cited by applicant]
Yang et al., “Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells,” Proc Natl Acad Sci USA., Oct. 14, 1997, 94(21):11478-11483.
[cited by applicant]
Booiman et al., “Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls,” PLoS One, Aug. 2017, 12(8):e0183357, 17 pa…
[cited by applicant]
Bouvin-Pley et al., “Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monocl…
[cited by applicant]
Collman et al., “An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1,” Journal of Virology, Dec. 1992, 66(12):7517-7521.
[cited by applicant]
Diskin et al., “Increasing the Potency and Breadth of an HIV Antibody by using Structure-Based Rational Design,” Science, Dec. 2011, 334(6060):1289-1293.
[cited by applicant]
Jonnalagadda et al., “Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy,” Molecular Therapy, Apr. 2015, 23(4):757-768.
[cited by applicant]
La Rosa et al., “MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults,” Blood, Jan. 2017, 129(1):114-125.
[cited by applicant]
Sok et al., “HIV Broadly Neutralizing Antibodies: Taking Good Care of the 98%,” Immunity, Nov. 2016, 45(5):958-960.
[cited by applicant]
Wang et al., “Engraftment of human central memory-derived effector CD8
[cited by applicant]
Wu et al., “Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1,” Science, Aug. 2010, 329(5993):856-861.
[cited by applicant]
Cooper et al., “Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1,” Blood, 2005, 105(4):1622-1631.
[cited by applicant]
Cruz et al., “Infusion of donor-derived CD19-redircted virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study,” Blood, 2013, 122(17):2965-2973.
[cited by applicant]
Diskin et al., “Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies,” J. Exp. Med., Jun. 3, 2013, 210(6):1235-1249.
[cited by applicant]
Finzi et al., “Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy,” Science, 1997, 278(5341):1295-1300 (Abstract Only).
[cited by applicant]
Hermankova et al., “Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymphocytes in Vivo,” J Virol, 2003, 77(13):7383-7392.
[cited by applicant]
Huang, “Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth,” Immunity, Nov. 15, 2015, 45(5):1108-1121.
[cited by applicant]
Kalos et al., “T cells with chimeric antigen receptors have patent antitumor effects and can establish memory in patients with advanced Leukemia,” Sci. Transl. Med., 2011, 3(95):95re73 (Abstract Only).
[cited by applicant]
Klein et al., “HIV therapy by a combination of broadly neutralizing antibodies in humanized mice,” Nature, 2012, 592(7427):118-122 (Abstract Only).
[cited by applicant]
La Rosa et al., “Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant,” Journal of Infectious Diseases, 2012, 205(8)…
[cited by applicant]
Leen et al., “Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-barr virus infections after haploidentical and matched unrelated stem cell transplantation,” Blood, 2009, 114(19…
[cited by applicant]
Pule et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, 2008, 14(11):1264-1270 (Abstract Only).
[cited by applicant]
Shan et al., “Stimulation of HIV-1 Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation,” Immunity, 2012, 36(3):491-501.
[cited by applicant]
Sloan et al., “Targeting HIV Reservoir of Infected CD4 T Cells by Dual-Affinity Re-Targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells,” PLoS Pathg., 2015, 11(11):e1005233, 29 pages.
[cited by applicant]
U.S. Appl. No. 18/856,156, filed Oct. 11, 2024, Wang et al.
[cited by applicant]
Leibman et al., “Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD-4 based chimeric antigen receptor,” PLoS Pathogens, Oct. 2017, 13(10):e1006613, 30 pages.
[cited by applicant]
Liu et al., “Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity,” Journal of Virology, Jul. 2015, 89(13):6685-6694.
[cited by applicant]
Wagner, “Quarter Century of Anti-HIV CAR T Cells,” Current HIV/AIDS Reports, Apr. 2018, 15(2):147-154.
[cited by applicant]